SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-24-000007
Filing Date
2024-01-08
Accepted
2024-01-08 07:03:29
Documents
15
Period of Report
2024-01-05
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20240105.htm   iXBRL 8-K 35395
2 EX-99.1 immunome-projectlionpressr.htm EX-99.1 21949
6 image_0.jpg GRAPHIC 12854
7 image_1.jpg GRAPHIC 11618
  Complete submission text file 0001725160-24-000007.txt   228654

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20240105.xsd EX-101.SCH 1904
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20240105_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20240105_pre.xml EX-101.PRE 13048
9 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20240105_htm.xml XML 2821
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 24518285
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)